| Journal of Immunology Publishes Study of Cleveland BioLabs' Drug CBLB502 in ... - Stock Markets Review |
|
|
Stock Markets Review Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a study demonstrating CBLB502's ability to inhibit acute renal ischemic failure was published in the October 1, 2011 issue of The Journal of Immunology (J Immunol 2011 187:3831-3839; |